Objective Neratinib plus capecitabine (Ner+Cap) were proved to be clinically beneficial as a third-line treatment for women with human epidermal growth factor receptor-2 (HER2) positive metastatic ...

There were approximately 725,000 new cases and 664,000 deaths worldwide due to hepatocellular carcinoma (HCC) in 2020. HCC comprises 75%-85% of primary liver cancer cases and is the fourth-leading ...

On Jan. 24, the FDA issued a warning about the enzyme deficiency in which it urged health care providers to “inform patients prior to treatment” about the risks of taking 5-FU and capecitabine. On ...

Around 300,000 people are treated with 5-FU or capecitabine in the United States each year, but its toxicity could well have prevented FDA approval were it up for approval today. Short of withdrawing ...

Background: Preoperative mFOLFIRINOX is a treatment option for patients (pts) with resectable/borderline resectable (R/BR) pancreatic ductal adenocarcinoma (PDAC).Methods: CASSANDRA (NCT04793932) is a ...

They randomly assigned 748 patients (median age, 59 years; range, 24-75; 69.7% men) to receive capecitabine and oxaliplatin plus either 12 mg daily anlotinib (days 1-14) or 7.5 mg/kg IV ...

In the CAPOX group, patients also received 1000 mg/m 2 capecitabine orally twice daily on days 1–14 every 3 weeks, plus 130 mg/m 2 oxaliplatin intravenously every 3 weeks. In the FP cohort, patients ...

Processa Pharmaceuticals, Inc., a clinical-stage company specializing in next-generation cancer therapies, announced the acceptance of three abstracts for presentation at the 2025 American Society ...